产品
编 号：F058622
分子式：C30H44O9
分子量：548.66
分子式：C30H44O9
分子量：548.66
产品类型
规格
价格
是否有货
结构图
CAS No: 1182-87-2
产品详情
生物活性：
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib.
体内研究：
Peruvoside (0.1 mg/kg，腹腔注射；一天一次，连续 28 天) 抑制肺癌小鼠模型的肿瘤生长。Peruvoside (0.59 mg/kg，腹腔注射；一天一次，连续 7 天) 降低了 EV-A71 感染小鼠模型的死亡率。Animal Model:Lung cancer mouse model
Dosage:0.1 mg/kg
Administration:Intraperitoneal injection (i.p.); Once daily for 28 days
Result:Reduced the tumour size to 129.9 mm3, which was significantly smaller than the control group (348 mm3).Significantly decreased levels of phosphorylated Src Y419 in tumourtissues compared with control tissues.
Animal Model:EV-A71-infected mice model
Dosage:0.59 mg/kg
Administration:Intraperitoneal injection (i.p.); Once daily for 7 days
Result:Substantially reduced clinical scores based on physical symptoms of body weight, activity,breathing, movement, and dehydration.Showed about 6 log reduction in viral titre with 99.9% efficacy in inhibiting virus.
体外研究：
Peruvoside (50-5000 nM，24 小时) 抑制了 PC9，PC9/gef，H3255，和 H1975 细胞系的活力和增殖。Peruvoside (0.005-0.5 μM, 72 小时) 与 Gefitinib (0.01~0.5 μM) 联用时，增强了 A549， PC9/gef 和 H1975 细胞对 Gefitinib 的敏感程度。Peruvoside (0-100 μM，24 小时) 诱导 MCF-7，HpG2 和 A549 细胞的周期停滞和凋亡[2。
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib.
体内研究：
Peruvoside (0.1 mg/kg，腹腔注射；一天一次，连续 28 天) 抑制肺癌小鼠模型的肿瘤生长。Peruvoside (0.59 mg/kg，腹腔注射；一天一次，连续 7 天) 降低了 EV-A71 感染小鼠模型的死亡率。Animal Model:Lung cancer mouse model
Dosage:0.1 mg/kg
Administration:Intraperitoneal injection (i.p.); Once daily for 28 days
Result:Reduced the tumour size to 129.9 mm3, which was significantly smaller than the control group (348 mm3).Significantly decreased levels of phosphorylated Src Y419 in tumourtissues compared with control tissues.
Animal Model:EV-A71-infected mice model
Dosage:0.59 mg/kg
Administration:Intraperitoneal injection (i.p.); Once daily for 7 days
Result:Substantially reduced clinical scores based on physical symptoms of body weight, activity,breathing, movement, and dehydration.Showed about 6 log reduction in viral titre with 99.9% efficacy in inhibiting virus.
体外研究：
Peruvoside (50-5000 nM，24 小时) 抑制了 PC9，PC9/gef，H3255，和 H1975 细胞系的活力和增殖。Peruvoside (0.005-0.5 μM, 72 小时) 与 Gefitinib (0.01~0.5 μM) 联用时，增强了 A549， PC9/gef 和 H1975 细胞对 Gefitinib 的敏感程度。Peruvoside (0-100 μM，24 小时) 诱导 MCF-7，HpG2 和 A549 细胞的周期停滞和凋亡[2。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备